Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Formulary Coverage & Prior Auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 EmblemHealth Formulary (US86) — Coverage Criteria

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered prescription drugs, tiers, and formulary rules for EmblemHealth members and explains prior authorization, quantity limits, step therapy, and how to use the formulary.

    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth Formulary (US86) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization for drugs labeled PA/LA/SP or when prescribed quantity exceeds documented quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    US86Formulary ID
    2026-04-01Effective
    Tier 1–2Tier Structure
    MultipleQuantity Limits
    SP/LA presentSpecialty Flags
    ~120+Drug entries (approx.)

    Coverage Criteria Overview

    This formulary listing is informational and coverage varies by plan. Not every drug shown will be paid for under every EmblemHealth benefit design; members and providers must consult the member's Certificate of Coverage or call member services to confirm whether a specific product is covered and what cost-sharing or prior authorization requirements apply. The policy notes: "Not all drugs in this list are paid for by all drug benefit plans; coverage is not guaranteed. Check your benefits."

    The formulary does not present a single list of explicit exclusions in these sections; instead, entries are shown with a Drug Tier and a Requirements/Limits column that may include flags such as OTC, QL (quantity limit), SP (specialty) or LA (limited access). These annotations and the documented quantity limits (for example, QL values for dexlansoprazole and esomeprazole) indicate utilization controls and program routing rather than a plain-text exclusion statement.

    Formulary Drug Entries and Sample Codes

    Sample listed drugs with tiersmixed
    amoxicillin (trihydrate) tab 500 mg, 875 mglisted with Drug Tier = 1
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mglisted with Drug Tier = 1
    ampicillin & sulbactam sodium for iv soln 3 (2-1) gmlisted with Drug Tier = 1
    ampicillin sodium for iv soln 1 gm, 2 gmlisted with Drug Tier = 2
    piperacillin sod-tazobactam na for inj 3.375 gm (3-0.375 gm)listed with Drug Tier = 1, Requirements/Limits = LA
    cefazolin sodium for iv soln 1 gmlisted with Drug Tier = 2
    ceftriaxone sodium for inj 250 mg, 500 mg, 1 gm, 2 gmlisted with Drug Tier = 1
    azithromycin tab 250 mg, 500 mg, 600 mglisted with Drug Tier = 1
    Formulary drug entries (sample)NDC | mixed
    norethindrone & ethinyl estradiol-fe chew tab 0.4 mg-35 mcglisted with Drug Tier = 1
    NUVARING - etonogestrel-ethinyl estradiol va ring 0.12-0.015 mg/24hrlisted with Drug Tier = 2
    OPILL - norgestrel tab 0.075 mglisted with Drug Tier = 2; Requirements/Limits = OTC
    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth Formulary (US86) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization for drugs labeled PA/LA/SP or when prescribed quantity exceeds documented quantity limits.
    SourceLink
    On This Page
    Coverage Criteria OverviewFormulary Drug Entries and Sample CodesProvider Actions, Prior Authorization, and DocumentationKey Terms and FlagsStep Therapy and Managed AccessQuantity Limits (QL) — Selected EntriesSite of Care and Specialty Pharmacy RoutingBackground and Purpose
    Endocrine agentsmixed
    medroxyprogesterone acetate tab 2.5 mg, 5 mg, 10 mg (Provera)Drug Tier = 1
    progesterone cap 100 mg, 200 mg (Prometrium)Drug Tier = 1
    levothyroxine sodium tab (multiple strengths) (Synthroid)Drug Tier = 1
    Products with utilization controlsmixed
    JYNARQUE - tolvaptan tab therapy packDrug Tier = 2; Requirements/Limits = LA, SP
    tolvaptan tab (Samsca) 15 mg, 30 mgDrug Tier = 1; Requirements/Limits = QL (30 or 60 tablets/365 days), SP
    Infusion/electrolyte productsmixed
    potassium chloride/sodium inj kcl 40 meq/l (0.298%) in nacl 0.9%Listed infusion product and concentration
    potassium chloride/sodium inj kcl 20 meq/l (0.15%) in nacl 0.9%Listed infusion product and concentration
    potassium phosphates inj 15 mm/5ml (phos) 22 meq/5ml (k), 45 mm/15ml (phos) 66 meq/15ml (k), 150 mm/50ml (phos) 220 meq/50ml (k)Potassium phosphates formulations
    Saline and sodium productsmixed
    sodium chloride flush iv soln 0.9%Saline flush
    sodium bicarbonate iv soln 4.2%, 8.4%Sodium bicarbonate IV solutions
    sodium phosphates inj 45 mm/15ml (phos) 60 meq/15ml (na)Sodium phosphates formulations
    Hematological / nutrientsmixed
    eltrombopag olamine (Promacta) powder pack 25 mg, 12.5 mgHematopoietic agent; Requirements/Limits = SP
    ferrous sulfate solutions (various strengths)Oral iron products; some designated OTC
    glutamine (Endari) powd pack 5 gmSickle cell agent; Requirements/Limits = SP
    Anticoagulantsmixed
    dabigatran etexilate (Pradaxa) cap 75 mg, 150 mg, 110 mgAnticoagulant with QL specified for some strengths
    apixaban (Eliquis) tabs 2.5 mg, 5 mg and sprinkle/oral suspensionAnticoagulant with QL noted for some forms
    enoxaparin sodium inj (Lovenox) prefilled syringes 30 mg/0.3ml, 80 mg/0.8mlLMWH with QL (30 syringes/90 days)
    rivaroxaban (Xarelto) tabs and suspensionAnticoagulant with QL for certain formulations
    warfarin sodium tabs 1-10 mgVitamin K antagonist; no QL listed
    Hemostaticsmixed
    aminocaproic acid inj 250 mg/ml; oral 0.25 gm/ml; tabs 500 mg, 1000 mgHemostatic agents
    tranexamic acid tab 650 mgHemostatic agent
    Ophthalmic productsmixed
    bimatoprost ophth soln 0.03% (LUMIGAN / generic)Ophthalmic prostaglandin analog; QL noted for some products (2.5 mls/30 days)
    latanoprost ophth soln 0.005% (Xalatan)Prostaglandin analog; QL (2.5 mls/30 days)
    nepafenac ophth susp 0.3% (ILEVRO)Ophthalmic NSAID; Drug Tier = 2
    moxifloxacin hcl ophth soln 0.5% (Vigamox)Ophthalmic fluoroquinolone
    tolvaptan quantity limits
    tolvaptan 15 mg (Samsca)Quantity limit: 30 tablets per 365 days (Requirements/Limits = QL), specialty flag = SP
    tolvaptan 30 mg (Samsca)Quantity limit: 60 tablets per 365 days (Requirements/Limits = QL), specialty flag = SP
    COMBIPATCH — 8 patches
    COMBIPATCH (estradiol-norethindrone patch)Quantity limit: 8 patches per 28 days (Requirements/Limits = QL (8 patches/28 days)).

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Likely for QL / LA / SP Products

    Prior authorization is commonly required for products flagged with QL (Quantity Limit), LA (Limited Availability), or SP (Specialty). When a drug in the formulary shows any of these Requirements/Limits codes, providers should assume prior authorization may be needed and contact Member Services or the plan’s provider portal to confirm and submit a PA request before dispensing.

    • Affected flags: QL, LA, SP
    • Examples: TOBI PODHALER (LA, SP); APRETUDE (LA, SP); many injectable biologic/antineoplastic agents marked SP or LA
    Prior Authorization

    Prior Authorization for SP‑Labeled Products

    Products explicitly labeled SP (Specialty) frequently require prior authorization due to special handling, monitoring, or distribution requirements. Injectable biologics and antineoplastic agents often carry SP and will generally be routed through specialty pharmacy or prior authorization workflows.

    • Common SP examples: rituximab (RUXIENCE) - Requirements/Limits = SP
    • Antineoplastics and many infusions show SP designation
    Note

    Specialty / Limited‑Access Annotations

    LA (Limited Availability) and SP (Specialty) annotations indicate products that may be routed through specialty channels or have limited pharmacy distribution. These flags can change where and how a prescription is filled and may require specialty pharmacy enrollment or shipment coordination.

    • LA = may be available only at select pharmacies
    • SP = specialty handling, may need patient education/monitoring
    • Examples: OFEV (LA, SP); JYNARQUE (LA, SP)
    Prior Authorization

    PA May Be Required for LA / SP / QL Products

    If a medication is marked LA, SP, or has a QL, providers should verify PA requirements before prescribing. Failure to obtain prior authorization when required may result in claim denial or member out‑of‑pocket responsibility.

    • Contact Member Services: 877-793-6253 (TTY: 711)
    • Check formulary Requirements/Limits code on the drug line
    • Obtain PA prior to dispensing when required
    Prior Authorization

    Specialty / Limited‑Access Products May Require Prior Authorization

    Specialty or limited‑access products (SP/LA) may require additional clinical documentation, prior authorization, or routing through a specialty pharmacy. Providers should prepare to submit indication, prior treatment history, and relevant labs or monitoring plans.

    • Examples: biologics (ENTYVIO, OMVOH), antineoplastics, and certain orphan drugs
    • Prepare diagnosis, prior therapy, and monitoring plan with PA submission
    Prior Authorization

    Tier 2 Inhaler Prior Authorization Likelihood

    Tier 2 inhalers and combination inhaled corticosteroid products often carry quantity limits and may require prior authorization for overrides. Verify QL values on the formulary (for example, 1 or 2 inhalers per 30 days) and include justification if requesting additional units.

    • Examples: ADVAIR HFA = QL (1 inhaler/30 days)
    • Albuterol inhalers = QL (2 inhalers/30 days)
    • TRELEGY/ANORO/ARNUITY have specific blister/quantity QLs
    Prior Authorization

    Specialty / Limited‑Access Agents Require Authorization

    Many specialty and limited‑access agents require authorization and may be subject to managed distribution, specialty pharmacy fill, or program-specific enrollment. Confirm payer routing and required forms ahead of treatment initiation.

    • Biologic examples: ENTYVIO (LA, SP), INFLECTRA (SP)
    • Oncology biologics and infused therapies commonly require PA and specialty routing
    Documentation Required

    Prior Authorization and Specialty Flags Impact Coverage

    Requirements/Limits flags (SP, LA, QL, ST, OTC) influence coverage decisions. When a drug line shows these flags, submit supporting clinical documentation and follow the plan’s PA checklist to avoid denials.

    • ST (Step Therapy) may require trials of preferred agents before approval
    • OTC or blank Requirements/Limits may affect benefit coverage
    • Use the drug’s Tier and Requirements/Limits code when preparing documentation
    Note

    Specialty / Limited Access Requirement

    Specialty and limited access flags typically mean additional administrative steps are required. Plans may require specialty pharmacy enrollment, specific dispensing sites, or case management prior to approval.

    • Examples: MAYZENT (LA, SP), MAVENCLAD (LA, SP)
    • Coordinate with specialty pharmacy to ensure timely start of therapy
    Prior Authorization

    Specialty / Injectable Products Handling

    Injectable, intra‑articular, and infused specialty products often need special handling and prior authorization. Ensure infusion centers, administration codes, and drug‑specific documentation are included with PA requests.

    • Intra‑articular products: SYNVISC, VISCO‑3 (Requirements/Limits noted)
    • Infused biologics/chemotherapy: many listed under ANTINEOPLASTIC AGENTS carry SP
    Documentation Required

    Prior Authorization and Coverage Handling

    When Requirements/Limits indicate prior authorization, provide clear clinical rationale, prior medication history, and any required lab or specialist documentation. Use the formulary Tier and Requirements/Limits codes to guide the PA submission.

    • Include Tier and Requirements/Limits line from formulary in the PA
    • Attach prior therapy notes, labs, and relevant specialty consults
    • Document quantity requested relative to QL limits
    Note

    Special Access Flags May Trigger Additional Review

    Special access flags such as LA or program‑specific annotations (e.g., SP, special program) may trigger additional review steps or enrollment in manufacturer or plan programs. Check the formulary entry for these flags and follow the plan’s special program instructions.

    • TOBI PODHALER listed LA, SP — may need special access handling
    • BEYFORTUS listed SP — may be routed through a specialty program
    Prior Authorization

    Special Program Flag May Require Authorization

    Some drugs carry a Special Program (SP) flag that requires program enrollment or additional administrative steps prior to coverage. Confirm program requirements and include required forms with the PA to avoid processing delays.

    • SP examples: BEYFORTUS, many antineoplastics and specialty immunologics
    • Confirm whether manufacturer or plan program enrollment is needed
    Denial Risk

    Requirements / Limits Flags May Trigger Denials

    Requirements/Limits flags can be grounds for denial if unmet. If a request exceeds quantity limits, lacks step‑therapy fulfillment, or omits required documentation, the claim is at higher risk for denial.

    • Potential denial triggers: exceeding QL, not meeting ST, missing PA
    • Example QLs: pregabalin strength‑specific QLs; anticoagulants with monthly QLs
    Denial Risk

    Potential Denial Trigger: Unmet Formulary Requirements / Limits

    Unmet formulary requirements — such as exceeding QLs, failing to follow ST, or not providing required documentation for LA/SP products — are common reasons for PA denial. Verify the formulary line and provide all requested clinical information.

    • Check QL numeric thresholds on formulary entries
    • Provide treatment history to satisfy ST when applicable
    Denial Risk

    Quantity Limit Exceedance — Action Required

    Quantity limits are enforced on many drug lines. Requests that exceed the stated QL should include clinical justification, prior authorization, and dosage rationale to support approval.

    • Common QL examples: abacavir soln QL (960 mls/30 days); lamivudine soln QL (960 mls/30 days)
    • Anticoagulants and inhalers frequently have QLs listed
    Prior Authorization

    Prior Authorization and Specialty Limits Present

    Specialty drugs frequently carry both prior authorization requirements and specialty limits. Expect additional documentation and case management steps for products such as monoclonal antibodies, infused agents, and certain orphan therapies.

    • Examples: ENTYVIO (LA, SP), OMVOH (LA, SP), MAVENCLAD (LA, SP)
    • Coordinate PA with specialty pharmacy to include administration schedule and monitoring plan
    Documentation Required

    Formulary / Requirements Implications for Documentation

    Formulary annotations (Tier, Requirements/Limits) determine coverage and documentation needs. When preparing a PA, cite the formulary line (drug name, strength, Tier, Requirements/Limits) and supply supporting clinical records.

    • Use the formulary Tier to justify medical necessity (e.g., Tier 2 vs Tier 1)
    • Include the exact Requirements/Limits text from the formulary in submissions
    Billing Rule

    Quantity Limits Trigger Coverage Review

    Quantity limits on the formulary often trigger coverage review. When requesting amounts above the QL, include dosing schedule, therapeutic rationale, and any weight‑ or regimen‑based calculations in the PA.

    • Inhaler QLs (e.g., 1 inhaler/30 days) require justification for additional fills
    • Anticoagulant and antiepileptic QLs listed should be referenced in request
    Documentation Required

    Brand vs. Generic Documentation

    When there is a brand vs. generic consideration, document the clinical rationale for brand‑necessary requests (allergy, intolerance, therapeutic failure of generics) and include previous medication trials in the PA.

    • If prescribing a brand product when generics exist, include prior trial and failure of generic alternatives
    • Document adverse reactions or clinical reasons for brand medical necessity
    Billing Rule

    Adhere to Quantity Limits

    Adhere to stated quantity limits; do not dispense amounts exceeding formulary QLs without an approved PA. Pharmacy and provider dispensing should reflect the QL units (tablets, inhalers, blisters, mLs) listed on the formulary.

    • Follow unit definition on formulary (e.g., inhaler, blister, tablets, mLs)
    • Request PA when more than QL is clinically necessary
    Documentation Required

    Quantity Limit Documentation

    Document quantity rationale in the PA: include dosing frequency, duration, and calculation leading to the total quantity requested. Attach prescribing notes and any relevant weight or body‑surface area calculations for specialty dosing.

    • For liquids: convert mL limits to dosing schedule in notes
    • For weight‑based dosing, attach calculation and patient weight/date
    Documentation Required

    Quantity Limits Documented on Formulary — Use in Submissions

    Formulary entries list QLs and other Requirements/Limits; reference these exact notations in PA requests. Use the formulary line item to show the plan’s published limit and explain why an exception is necessary.

    • Cite formulary line (drug, strength, Requirements/Limits text) in the PA cover letter
    • Attach the formulary page or excerpt when feasible
    Billing Rule

    Required Prescription Details

    Prescriptions should include complete details: drug name (brand and generic), strength, dosage form, quantity, days’ supply, and route of administration. For specialty or infused products, include administration site, infusion schedule, and payer‑required codes.

    • Include NDC or exact product description when possible
    • Specify route (IV, SC, IM, inhalation, intra‑articular) and administration setting
    Documentation Required

    Provide Documentation When Requirements / Limits Apply

    Provide all relevant documentation when Requirements/Limits apply: diagnosis, prior therapies and outcomes, lab results, specialist notes, and dosing rationale. Incomplete submissions increase denial risk and delay therapy.

    • Attach prior medication failure documentation for ST requirements
    • Include labs or imaging tied to the indication where required
    Documentation Required

    Use Tier and Requirements/Limits When Documenting

    When documenting a PA for a specialty product, include the product’s Tier and the Requirements/Limits designation (SP/LA/QL) on the cover sheet. This ensures the reviewer sees the formulary context and applicable plan limits.

    • Place Tier and Requirements/Limits prominently in the submission
    • For SP products, note any required specialty program or distribution channel
    Prior Authorization

    Specialty Product Designation — Provider Actions

    Specialty product designation (SP) indicates the need for specialty pharmacy coordination, additional monitoring, and often a higher documentation burden. Start authorization and specialty enrollment early to avoid treatment delays.

    • SP examples: many antineoplastics, biologics, and orphan drugs listed on the formulary
    • Initiate specialty PA and enrollment prior to first dose
    Step Therapy

    Step / Managed Therapy Indications — Step Therapy Not Specified

    Step therapy indications are present in the formulary abbreviations (ST) but explicit step sequences are not listed for every agent in this section. If ST is shown on a drug line, expect to document prior trials of preferred agents; where no explicit sequence is provided, follow plan guidance or contact Member Services.

    • ST flag: provider must show trials of required agents before approval
    • When step sequences are not specified, contact Member Services for guidance
    Step Therapy

    Managed Access / Potential Step Edits

    Managed access and potential step edits may be applied even when explicit step therapy rules are not printed on the line. Assume utilization management may include step edits and verify requirements before prescribing.

    • Examples: inhaled antibiotics and specialty formulations often carry SP/LA and may also have step requirements
    • Contact Member Services if uncertain about step requirements

    Key Terms and Flags

    PA — Prior Authorization
    DefinitionPA (Prior Authorization) — the plan requires the member or prescriber to get approval before the prescription will be covered; failure to obtain approval may result in noncoverage.
    QL — Quantity Limit
    DefinitionQL (Quantity Limit) — a specified maximum amount of a drug the plan will cover within a stated time period (examples include tablets per 30 days or mLs per 30 days).
    PurposeLimits dispensing to the listed quantity (e.g., QL (2 inhalers/30 days) for albuterol HFA).
    Common reportingShown in Requirements/Limits next to product lines (e.g., QL (960 mls/30 days) for some oral solutions).
    ST — Step Therapy
    DefinitionST (Step Therapy) — the plan may require trying specified drugs first to treat a condition before covering alternatives; exceptions may be requested.
    ApplicationStep requirements are invoked where documented; this listing contains no explicit step sequences in the shown extract.
    SP — Specialty Drugs
    DefinitionSP (Specialty Drugs) — drugs that may require special handling, patient monitoring, unique education, or specialty pharmacy processing.
    IndicationAppears in Requirements/Limits as 'SP' for high-cost biologics, certain oral specialty agents, and therapy packs (e.g., rituximab, cladribine).
    SP / LA — flag examples
    Examples of flagsLA (Limited Availability) and SP (Specialty) appear as Requirements/Limits flags on product lines (examples: TOBI PODHALER = LA, SP; APRETUDE = LA, SP).
    ImplicationThese flags indicate specialty routing or limited-access handling and may require prior authorization or specialty pharmacy dispensing.
    Source entriesSee TOBI PODHALER (chunk 23), APRETUDE and other LA/SP entries (chunk 26), tolvaptan entries marked SP (chunk 81).
    QL — explicit maximum supply examples
    Explicit maximum supply formatQL values are shown with a numeric maximum and time period (e.g., QL (960 mls/30 days), QL (60 tablets/30 days), QL (2 inhalers/30 days)).
    Formulation examplesOral solutions (mLs), inhalers (canisters), capsules/tablets per 30/90/365 days are listed with QL in Requirements/Limits.
    Ophthalmic exampleLatanoprost/bimatoprost ophthalmic solutions shown as QL (2.5 mls/30 days).
    LA — Limited Access
    DefinitionLA (Limited Access) — payer-defined restriction or routing; may limit where a product can be obtained and often requires specific authorization.
    Common useApplied to certain injectables and specialty-administered agents (flags appear in Requirements/Limits).
    OTC — Over-the-counter
    DefinitionOTC (Over-the-counter) — product available without a prescription; listed with Requirements/Limits = OTC for nonprescription items (e.g., nicotine gum, prenatal vitamins).
    Coverage noteOTC designation appears in the Requirements/Limits column and may affect whether a product requires a prescription for coverage.
    QL example — tolvaptan QL
    tolvaptan QL (15 mg)QL: 30 tablets per 365 days (tolvaptan 15 mg, Requirements/Limits shows QL and SP)
    tolvaptan QL (30 mg)QL: 60 tablets per 365 days (tolvaptan 30 mg, Requirements/Limits shows QL and SP)
    Drug Tier — definition of tier field
    DefinitionDrug Tier — formulary tier assignment for each product; numeric tiers are shown in the Drug Tier column and influence member cost-sharing and coverage preference.
    UsageUse tier value to determine plan coverage level (tiers 1–2 shown in this extract).
    Requirements/Limits — explanation of this policy column
    Column purpose'Requirements/Limits' — policy column describing special coverage notes such as QL (quantity limits), SP (specialty), LA (limited access), or OTC designations for each product.
    Action implicationWhen Requirements/Limits contains a flag or QL, providers should supply supporting documentation or follow prior authorization/specialty processes as required.

    Step Therapy and Managed Access

    Coverage labelSummary
    managed_access
    Step therapy (ST) may require members to try preferred agents first; exceptions can be requested. Policy defines ST as attempting specified drugs before covering alternatives.
    Coverage labelExamples / notes
    managed_product
    Products marked LA or SP (examples: TOBI PODHALER — LA, SP; APRETUDE — LA, SP; PURIXAN — Requirements/Limits = LA, SP; BEYFORTUS — Requirements/Limits = SP). These entries indicate managed distribution and may require prior authorization or specialty routing.
    Coverage labelImplication for coverage
    specialty_prior_auth
    Entries annotated SP frequently indicate specialty program enrollment or prior authorization is required before the plan will cover the product (e.g., many injectable biologics and hematopoietic agents marked SP).
    Coverage labelInterpretation
    SP/LA_annotation
    Agents annotated with SP or LA (for example: TOBI PODHALER, mitomycin, OMVOH, RINVOQ) signal specialty routing or limited access; these flags imply additional enrollment, prior authorization, or site-of-care restrictions prior to coverage.
    Coverage labelObservation
    no_step_sequences
    Multiple formulary segments show no explicit step-therapy sequences listed; entries display tiers and Requirements/Limits fields but do not specify step order or required prior agents.
    Coverage labelNote
    tiering_present
    Tier assignments (Tier 1 or 2) are present across many entries, but explicit step-therapy rules are not specified in these chunks; tiering alone does not define ST sequences.
    Coverage labelImplication
    tier2_inhalers
    Tier 2 inhaled corticosteroid/combination inhalers (e.g., ADVAIR HFA, BREO ELLIPTA) are shown with QL entries (e.g., QL 1 inhaler/30 days), suggesting common utilization controls such as step edits or prior authorization pathways may apply.
    Coverage labelSummary
    no_explicit_ST_for_listed_drugs
    For many listed drugs in these chunks (e.g., sumatriptan products, gout agents, local anesthetics), no explicit step-therapy steps are provided in the formulary extract.
    Coverage labelDetails
    opioid_use_disorder_agents
    Opioid use disorder/buprenorphine products list quantity limits and dispensing limits (examples: buprenorphine sublingual tablets QL 6 tablets/90 days; buprenorphine-naloxone films QL 120 films/30 days), indicating utilization controls and potential channel or PA requirements.
    Coverage labelImplication
    immunomodulators_SP_LA
    Certain immunomodulators and targeted agents (OTEZLA, RINVOQ, XELJANZ) are designated SP or LA, SP in the listing; these flags suggest managed access and that step edits or prior authorization may be enforced by the plan before coverage.
    Coverage labelGeneral note
    no_explicit_step_sequences_general
    Across multiple segments, the formulary does not provide explicit step-therapy sequences; entries typically show drug tier and Requirements/Limits flags rather than ordered step algorithms.
    Coverage labelPractice implication
    specialty_routing_prior_to_coverage
    Specialty-labeled drugs (SP) and certain LA-designated products (e.g., hematopoietic agents, select antineoplastics) are likely to follow specialty program rules or require prior authorization/enrollment in a specialty channel prior to coverage.

    Quantity Limits (QL) — Selected Entries

    abacavir sulfate soln 20 mg/ml — 960 mls
    abacavir sulfate oral solution 20 mg/mLQuantity limit: 960 mLs per 30 days (Requirements/Limits = QL (960 mls/30 days)).
    Biktarvy (bictegravir-emtricitabine-tenof) — 30 tablets
    Biktarvy (bictegravir-emtricitabine-tenofovir alafenamide)Quantity limit: 30 tablets per 30 days (Requirements/Limits = QL (30 tablets/30 days)).
    lamivudine oral soln 10 mg/ml (Epivir) — 960 mls
    lamivudine oral solution 10 mg/mL (Epivir)Quantity limit: 960 mLs per 30 days (Requirements/Limits = QL (960 mls/30 days)).
    oseltamivir phosphate (Tamiflu) caps 30 mg — 40 capsules
    oseltamivir phosphate (Tamiflu) capsules 30 mgQuantity limit: 40 capsules per 120 days (Requirements/Limits = QL (40 capsules/120 days)).
    nitazoxanide 500 mg — QL 12 tablets (90 days referenced)
    nitazoxanide 500 mg tabletsQuantity limit: 12 tablets per 90 days (Requirements/Limits = QL (12 tablets/90 days)).
    CLIMARA PRO — 4 patches
    CLIMARA PRO (estradiol-levonorgestrel patch)Quantity limit: 4 patches per 28 days (Requirements/Limits = QL (4 patches/28 days)).
    estradiol gel (Estrogel) — 1 pump QL
    estradiol gel (Estrogel)Quantity limit: 1 pump per 30 days (Requirements/Limits = QL (1 pump/30 days)).
    Divigel estradiol td gel/packets — 30 packets or 37.5 grams
    Divigel estradiol topical gel/packetsQuantity limit: 30 packets per 30 days or 37.5 grams per 30 days (Requirements/Limits = QL (30 packets/30 days) or QL (37.5 grams/30 days)).
    tolvaptan tab 15 mg (Samsca) — 30 tablets
    tolvaptan tablet 15 mg (Samsca)Quantity limit: 30 tablets per 365 days (Requirements/Limits = QL (30 tablets/365 days)); SP flag present
    tolvaptan tab 30 mg (Samsca) — 60 tablets
    tolvaptan tablet 30 mg (Samsca)Quantity limit: 60 tablets per 365 days (Requirements/Limits = QL (60 tablets/365 days)); SP flag present
    tadalafil 2.5 mg and 5 mg — 30 tablets
    tadalafil 2.5 mg and 5 mgQuantity limit: 30 tablets per 30 days (Requirements/Limits = QL (30 tablets/30 days)).
    albuterol inhaler (various) — 2 inhalers
    albuterol inhaler (various)Quantity limit: 2 inhalers per 30 days (Requirements/Limits = QL (2 inhalers/30 days)).
    Advair HFA — 1 inhaler
    Advair HFAQuantity limit: 1 inhaler per 30 days (Requirements/Limits = QL (1 inhaler/30 days)).
    Breo Ellipta 50-25 — 1 inhaler
    Breo Ellipta 50-25Quantity limit: 1 inhaler per 30 days (Requirements/Limits = QL (1 inhaler/30 days)).
    dexlansoprazole (Dexilant) — strength-specific QL
    dexlansoprazole (Dexilant) 30 mgQuantity limit: 60 capsules per 30 days for 30 mg strength; 30 capsules per 30 days for 60 mg strength (Requirements/Limits lists strength-specific QLs).
    esomeprazole (Nexium) — QL 60 capsules/30 days and packets
    esomeprazole (Nexium)Quantity limit: QL 60 capsules/30 days for packet and capsule variants as specified (Requirements/Limits = QL (60 packets/30 days) for some forms).
    lanthanum carbonate (Fosrenol) — strength-specific QLs
    lanthanum carbonate (Fosrenol)Quantity limit: strength-specific QLs — 270 / 180 / 120 tablets per 30 days depending on strength (Requirements/Limits lists these strength-based QLs).
    oxybutynin solution — QL 600 mls/30 days
    oxybutynin solutionQuantity limit: 600 mLs per 30 days (Requirements/Limits = QL (600 mls/30 days)).
    vaginal estradiol cream — QL 255 grams/365 days
    vaginal estradiol cream (Estrace)Quantity limit: 255 grams per 365 days (Requirements/Limits = QL (255 grams/365 days)).
    MYRBETRIQ (mirabegron) — QL 30 tablets/30 days
    MYRBETRIQ (mirabegron)Quantity limit: 30 tablets per 30 days (Requirements/Limits = QL (30 tablets/30 days)).
    clonidine er 0.1 mg — 120 tablets
    clonidine ER 0.1 mgQuantity limit: 120 tablets per 30 days (Requirements/Limits = QL (120 tablets/30 days)).
    dexmethylphenidate ER (Focalin XR) 5-20 mg — 60 capsules
    dexmethylphenidate ER (Focalin XR) 5-20 mgQuantity limit: 60 capsules per 30 days (Requirements/Limits = QL (60 capsules/30 days)).
    dexmethylphenidate ER (Focalin XR) 25-40 mg — 30 capsules
    dexmethylphenidate ER (Focalin XR) 25-40 mgQuantity limit: 30 capsules per 30 days (Requirements/Limits = QL (30 capsules/30 days)).
    dexmethylphenidate tab (Focalin) 2.5 mg — 240 tablets
    dexmethylphenidate (Focalin) 2.5 mgQuantity limit: 240 tablets per 30 days (Requirements/Limits = QL (240 tablets/30 days)).
    guanfacine ER (Intuniv) 1 mg/4 mg — 30 tablets
    guanfacine ER (Intuniv) 1 mg / 4 mgQuantity limit: 30 tablets per 30 days (Requirements/Limits = QL (30 tablets/30 days)).
    guanfacine ER (Intuniv) 2 mg — 90 tablets
    guanfacine ER (Intuniv) 2 mgQuantity limit: 90 tablets per 30 days (Requirements/Limits = QL (90 tablets/30 days)).
    lisdexamfetamine (Vyvanse) — 30 capsules
    lisdexamfetamine (Vyvanse)Quantity limit: 30 capsules per 30 days (Requirements/Limits = QL (30 capsules/30 days)).
    methylphenidate ER (Concerta) 18-36 mg — 60 tablets
    methylphenidate ER (Concerta) 18-36 mgQuantity limit: 60 tablets per 30 days (Requirements/Limits = QL (60 tablets/30 days)).
    methylphenidate ER osmotic 54 mg — 30 tablets
    methylphenidate ER osmotic 54 mg (Concerta)Quantity limit: 30 tablets per 30 days (Requirements/Limits = QL (30 tablets/30 days)).
    methylphenidate 5 mg (Ritalin) — 360 tablets
    methylphenidate 5 mg (Ritalin)Quantity limit: 360 tablets per 30 days (Requirements/Limits = QL (360 tablets/30 days)).
    cladribine tab therapy pack — SP (special program)
    cladribine tablet therapy packRequirement: SP (special program/specialty) — listed as SP in Requirements/Limits
    dalfampridine (Ampyra) — SP
    dalfampridine (Ampyra) 10 mg ERRequirement: SP (listed as specialty in Requirements/Limits)
    nicotine polacrilex gum 2 mg/4 mg — OTC
    nicotine polacrilex gum 2 mg / 4 mgDesignation: OTC (Requirements/Limits = OTC)
    buprenorphine SL tab — 6 tablets
    buprenorphine sublingual tabletQuantity limit: 6 tablets per 90 days (Requirements/Limits = QL (6 tablets/90 days)).
    buprenorphine-naloxone films (Suboxone) — 120 films
    buprenorphine-naloxone films (Suboxone)Quantity limit: 120 films per 30 days (Requirements/Limits = QL (120 films/30 days)).
    fentanyl citrate preservative free inj — listed (no quantity specified)
    fentanyl citrate preservative-free injectionListed (Requirements/Limits present in product line; no explicit QL shown in extract)
    hydrocodone-acetaminophen various — 180 tablets (examples)
    hydrocodone-acetaminophen (various strengths)Quantity limits shown for many formulations (examples: QL 180 tablets/30 days; some strengths QL 240 tablets/30 days).
    hydrocodone-acetaminophen 2.5-325 mg — 240
    hydrocodone-acetaminophen 2.5-325 mgQuantity limit: 240 tablets per 30 days (Requirements/Limits = QL (240 tablets/30 days)).
    hydrocodone-acetaminophen various — 180
    hydrocodone-acetaminophen (other strengths)Quantity limit: 180 tablets per 30 days (Requirements/Limits = QL (180 tablets/30 days)).
    hydromorphone liquid (Dilaudid) — 1440
    hydromorphone liquid (Dilaudid) 1 mg/mLQuantity limit: 1440 mLs per 30 days (Requirements/Limits = QL (1440 mls/30 days)).
    meperidine oral soln 50 mg/5ml — 1800
    meperidine oral solution 50 mg/5 mLQuantity limit: 1800 mLs per 30 days (Requirements/Limits = QL (1800 mls/30 days)).
    meperidine tab 50 mg — 360
    meperidine tablets 50 mgQuantity limit: 360 tablets per 30 days (Requirements/Limits = QL (360 tablets/30 days)).
    methadone soln 5 mg/5ml — 900
    methadone solution 5 mg/5 mLQuantity limit: 900 mLs per 30 days (Requirements/Limits = QL (900 mls/30 days)).
    morphine sulfate oral soln 10 mg/5ml — 2700
    morphine sulfate oral solution 10 mg/5 mLQuantity limit: 2700 mLs per 30 days (Requirements/Limits = QL (2700 mls/30 days)).
    morphine sulfate oral soln 20 mg/5ml — 1350
    morphine sulfate oral solution 20 mg/5 mLQuantity limit: 1350 mLs per 30 days (Requirements/Limits = QL (1350 mls/30 days)).
    morphine sulfate oral soln 100 mg/5ml — 270
    morphine sulfate oral solution 100 mg/5 mL (20 mg/mL)Quantity limit: 270 mLs per 30 days (Requirements/Limits = QL (270 mls/30 days)).
    oxycodone/acetaminophen (Percocet) — 360
    oxycodone/acetaminophen (Percocet)Quantity limit: 360 tablets per 30 days (Requirements/Limits = QL (360 tablets/30 days)).
    oxycodone 5 mg — 360
    oxycodone 5 mgQuantity limit: 360 tablets per 30 days (Requirements/Limits = QL (360 tablets/30 days)).
    oxycodone concentrate 100 mg/5ml — 270
    oxycodone concentrate 100 mg/5 mL (20 mg/mL)Quantity limit: 270 mLs per 30 days (Requirements/Limits = QL (270 mls/30 days)).
    oxycodone soln 5 mg/5ml — 5400
    oxycodone solution 5 mg/5 mLQuantity limit: 5400 mLs per 30 days (Requirements/Limits = QL (5400 mls/30 days)).
    oxycodone/acetaminophen 2.5-300 mg — 360
    oxycodone/acetaminophen 2.5-300 mg, 5-300 mgQuantity limit: 360 tablets per 30 days (Requirements/Limits = QL (360 tablets/30 days)).
    oxycodone/acetaminophen 10-300 mg — 180
    oxycodone/acetaminophen 10-300 mgQuantity limit: 180 tablets per 30 days (Requirements/Limits = QL (180 tablets/30 days)).
    oxymorphone tab — 180
    oxymorphone tabletsQuantity limit: 180 tablets per 30 days (Requirements/Limits = QL (180 tablets/30 days)).
    tramadol 50 mg — 240
    tramadol 50 mgQuantity limit: 240 tablets per 30 days (Requirements/Limits = QL (240 tablets/30 days)).
    tramadol 100 mg — 120
    tramadol 100 mgQuantity limit: 120 tablets per 30 days (Requirements/Limits = QL (120 tablets/30 days)).
    tramadol-acetaminophen 37.5-325 mg — 240
    tramadol-acetaminophen 37.5-325 mgQuantity limit: 240 tablets per 30 days (Requirements/Limits = QL (240 tablets/30 days)).
    ibuprofen suspension 100 mg/5ml — OTC
    ibuprofen suspension 100 mg/5 mLDesignation: OTC (Requirements/Limits = OTC)
    ketorolac 10 mg — 20
    ketorolac 10 mg tabletsQuantity limit: 20 tablets (Requirements/Limits = QL (20 tablets/5 days)).
    pregabalin — strength-specific QLs
    pregabalin (various strengths)Strength-specific QLs listed (examples: 360/30d for 25 mg; 270/30d for 50 mg; 180/30d for 75/100 mg; 90/30d for 150/200 mg; 60/30d for higher strengths).
    dabigatran (Pradaxa) — 60/120 caps
    dabigatran (Pradaxa)QL: 60 capsules/30 days (75 mg) or 120 capsules/30 days (110 mg) (Requirements/Limits = QL).
    apixaban (Eliquis) — 60/74 tablets/capsules
    apixaban (Eliquis)QL: 60 tablets/30 days for some strengths; 74 capsules/30 days for sprinkle formulation (Requirements/Limits = QL).
    enoxaparin (Lovenox) prefilled syringes — 30 syringes/90 days
    enoxaparin (Lovenox) prefilled syringesQL: 30 syringes per 90 days (Requirements/Limits = QL (30 syringes/90 days)).
    rivaroxaban (Xarelto) — 620 mls/30 days (suspension)
    rivaroxaban (Xarelto) suspensionQL: 620 mLs per 30 days for certain suspension formulation (Requirements/Limits = QL (620 mls/30 days)).
    latanoprost/bimatoprost ophthalmic solutions — 2.5 mls/30 days
    latanoprost / bimatoprost ophthalmic solutionsQL: 2.5 mLs per 30 days (Requirements/Limits = QL (2.5 mls/30 days)).

    Site of Care and Specialty Pharmacy Routing

    Note

    Route LA/SP products to infusion center or specialty pharmacy

    Certain injectable or specialty-administered products and long-acting injectables marked LA or SP indicate limited access or specialty distribution and may be routed to infusion center or specialty pharmacy.

    • Examples: APRETUDE (LA, SP) and TOBI PODHALER (LA, SP) — coordinate with specialty pharmacy or infusion center as required.
    Note

    Use LA/SP flags to determine site-of-care routing

    LA and SP flags indicate specialty or limited-access site/process; follow specialty distribution or infusion routing when these flags are present on the formulary entry.

    • Verify site-of-care instructions and coordinate scheduling at an infusion center or specialty pharmacy when needed.
    Note

    IV biologics with LA/SP often require infusion or specialty distribution

    IV biologics listed with LA or SP flags (e.g., ENTYVIO, OMVOH, SELARSDI, TREMFYA) suggest infusion center or specialty distribution requirements — confirm PA and channel prior to administration.

    • For IV biologics, obtain PA and coordinate infusion center scheduling or specialty pharmacy fulfillment as indicated.
    Note

    Route SP/LA, SP products through specialty pharmacy

    Products labeled SP or LA, SP indicate specialty pharmacy or limited access handling (examples include tocilizumab, apremilast, upadacitinib); route these to specialty pharmacy and obtain required authorizations.

    • Check the Requirements/Limits field and contact specialty pharmacy for enrollment or dispensing instructions.
    Note

    Administer intra‑articular injectables in office/clinic as indicated

    Intra-articular hyaluronic acid products (GEL-ONE, SYNVISC, VISCO-3) are likely administered in office/clinic or infusion setting; verify site-of-care and any PA requirements before scheduling.

    • Confirm site-of-care and PA for intra-articular injections prior to administration.
    Billing Rule

    Dispense SP products via specialty pharmacy when required

    Specialty-designated products (SP) may require specialty pharmacy dispensing or channel; confirm specialty routing and authorization requirements before prescribing or dispensing.

    • If an item is labeled SP, coordinate with the specialty pharmacy and include specialty program documentation in PA requests.

    Background and Purpose

    Formularies provide a catalog of covered medications plus the management rules that guide prescribing and pharmacy dispensing. This document identifies drug tier assignments, utilization controls such as Prior Authorization (PA), Quantity Limits (QL), and Step Therapy (ST), and flags some products as Specialty (SP) or Limited Access (LA). The information is intended to help providers, pharmacists, and members determine likely coverage, required documentation, and appropriate site-of-care or specialty pharmacy handling.